FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
Reply |
|
Thread Tools | Display Modes |
09-28-2011, 01:33 PM | #1 | ||
|
|||
Member
|
Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease
The Sacramento Bee, Adamas Pharmaceuticals, Inc., Published: Wednesday, Sep. 28, 2011 - 4:11 am EMERYVILLE, Calif., Sept. 28, 2011 -- /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease. Called EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia), this study will evaluate the safety and effectiveness of three dose levels of ADS-5102 in the treatment of LID. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Update Phase 2b CERE-120 | Parkinson's Disease Clinical Trials | |||
Neurosearch AS said it has initiated phase I clinical studies of the drug candidate A | Parkinson's Disease Clinical Trials | |||
Cere120 Phase I Update | Parkinson's Disease Clinical Trials | |||
MJF Foundation...$1Mil...Critical Next Steps Projects Initiated/Comm. Fast Track 2005 | Parkinson's Disease |